The value of the Growing prevalence of cancer and the need for innovative and aggressive treatment to drive the particle therapy system market is projected to grow to $1,634.4 million with an estimated CAGR of 8.3% by 2030
Particle therapy is a cutting-edge area of external beam radiotherapy. For the treatment of cancer, it uses energetic neutron beams, protons, or other heavier positive ions. Cancer is the world's second leading cause of death. As stated by the American Cancer Society, more than 40,000 people in the United States were diagnosed with head and neck cancer in 2014. Head and neck cancer accounts in the United States for almost 5-6% of cancer cases. In addition, according to the World Health Organization (WHO), approx 9.6 million deaths were estimated and around one in six deaths occurred worldwide due to cancer in 2018. Therefore, the rising incidence of cancer patients worldwide is increasing the demand for particle therapy for cancer, which contributes to the growth of the global particle therapy systems market. Investigation of particle therapy for cancer have helped to elucidate many basic radiobiological ideas such as linear energy transfer, relative biological effectiveness, oxygen effect, and oxygen enhancement. Particle therapy is radiotherapy with an external pulse. This incorporates research in physics and its application in oncology. The non-invasive aspect of particle therapy acts as a major advantage in cancer treatment. However, infrastructure restriction in the healthcare industry and restricted reimbursements may hamper the market growth.
Particle system therapy system in prostate cancer is likely to hold the largest revenue over the forecast period
According to the American Cancer Society, approx 191,930 new cases of prostate cancer were estimated and nearly 33,330 death toll from prostate cancer occurred in 2019. Hence, in terms of providing treatment for prostate cancer, the demand for particle therapy is also rising, which further boosts the growth of the global market. Furthermore, proton therapy is among the most commonly used forms of particle therapy, and uses proton beams to irradiate cancer tissues.
North America and Asia Pacific to spearhead the global market during the forecast period
North America is expected to dominate the global market over the forecast period. The market is driven by factors such as growing cancer incidences, the substitution of older treatments with newer ones and the availability of radiation therapy reimbursements. The United States presents itself as the largest radiotherapy market that contributes to the growth of the North America particle therapy system market.
Asia Pacific is likely to be the fastest-growing market due to the increasing expenditure in oncology studies along with the treatment and availability of reimbursement policies in developing countries such as China and India, further fueling the significant growth in this region.
Key Market Players
- Danfysik A/S
- Hitachi, Ltd.
- Ion Beam Applications Sa (IBA)
- Mevion Medical Systems, Inc.
- Optivus Proton Therapy, Inc.
- Protom International, Inc.
- Provision Healthcare, LLC
- Sumitomo Heavy Industries, Ltd.
- Varian Medical Systems, Inc.
particle therapy system market Scope
|Forecast Unit||Value (USD)|
|Revenue forecast in 2030||$1,634.4 million|
|Growth Rate||CAGR of 8.3 % during 2022-2030|
|Segment Covered||by Type, System, Cancer Type, Application, End User, Region.|
|Regions Covered||North America, Europe, Asia Pacific, South America, Middle East and Africa|
|Key Players Profiled||IBA Worldwide (EU), Mevion Medical Systems (US), Varian Medical Systems, Inc. (US), Sumitomo Heavy Industries, Ltd. (Japan), Hitachi, Ltd. (Japan), Toshiba Medical Systems Corporation (Japan), and Provision Healthcare, LLC (US) among others.|
Key Segment Of The particle therapy system market
Based on Type, 2022-2030 (USD Million)
• Proton Therapy
• Heavy Ion Therapy
Based on Product & Service, 2022-2030 (USD Million)
Based on System, 2022-2030 (USD Million)
• Multi-Room Systems
• Single-Room Systems
Based on Cancer Type, 2022-2030 (USD Million)
• Pediatric Cancer
• Prostate Cancer
• Lung Cancer
• Breast Cancer
• Head and Neck Cancer
Based on Application, 2022-2030 (USD Million)
• Treatment Application
• Research Application
Based on End User, 2022-2030 (USD Million)
• Academic & Research Centers
Regional Overview, 2022-2030 (USD Million)
• Rest of Europe
• Rest of Asia Pacific
• Rest of South America
Middle East and South Africa